Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Stopped Sponsor decision to terminate the study because the study did not meet the primary endpoint.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

• DRUG: Motesanib
• DRUG: Placebo
• DRUG: Paclitaxel
• DRUG: Carboplatin

Sponsor

Takeda